Pfizer exercises option on Voyager TRACER capsid for rare CNS disease; $10M fee

Voyager Therapeutics, Inc.

Pfizer exercised License Option for Voyager's novel capsid for an undisclosed rare neurologic CNS disease gene therapy program.
Voyager receives $10M upfront fee and is eligible for future development, regulatory and sales milestone payments plus royalties.
Pfizer did not exercise option for cardiovascular target; rights for that target revert to Voyager.
Option follows prior agreement from Oct 2021 under which Pfizer evaluated Capsids through Sept 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.